A Phase IB Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) Given Orally in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors.

Trial Profile

A Phase IB Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) Given Orally in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2011

At a glance

  • Drugs Carboplatin; Paclitaxel; Panobinostat
  • Indications Gastrointestinal cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 12 Sep 2011 Last checked against ClinicalTrials.gov record.
    • 12 Sep 2011 Planned End Date changed from 1 Jun 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
    • 12 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top